Navigation Links
Non-Profit Shares Concerns with FDA on Avastin Breast Cancer Recommendation

ARDMORE, Pa., Dec. 16, 2010 /PRNewswire-USNewswire/ -- Dr. Marisa Weiss, president and founder of and a breast oncologist in the Philadelphia area submitted a letter to the U.S. Food and Drug Administration prior to the Oncology Drug Advisory Committee (ODAC) meeting to review data for Avastin's use in metastatic HER2-negative breast cancer.  In light of today's news that the FDA has recommended removing Avastin's approval to treat breast cancer, is making public Dr. Weiss' ODAC letter in its entirety.'s position remains unchanged by today's ruling.  

Dear ODAC Committee Members:

As you consider label changes for Avastin, asks you to consider the treatment needs, expectations, and preferences of women diagnosed with metastatic breast cancer. In contrast to most women with early-stage breast cancer, most women with metastatic disease need continuous treatment in order to live. Despite the desperation many people with metastatic disease experience, they often have a remarkable ability to measure the pros and cons of each treatment decision with purpose, clarity, and precision. No two women or their cancers nor their treatment histories are the same. Aggregate clinical trial results include individuals with greater than expected benefit as well as those with a disappointing response. We doctors are limited in our ability to figure out who will and who won't get the important benefit of any particular treatment whether in the first-line setting or beyond. But we must have treatment options to turn to for our patients who need and desire them. Women with metastatic disease are prepared to make treatment decisions with greater risk since prior forms of treatments have already failed them. They deserve that choice.

As a non-profit organization dedicated to providing the most reliable, complete, and up-to-date information about breast health and breast cancer, is committed to help everyone affected by breast cancer -- including family members and caregivers -- make sense of complex medical information so they can make the best decisions for their unique situations. Hundreds of thousands of women diagnosed with metastatic breast cancer have turned to to better understand their available treatment options, as well as the results of studies that may influence their future treatment choices.

Through 10 years of dialogue with women diagnosed with metastatic breast cancer, has learned a great deal from these women about their feelings, perspectives, needs, and experiences with the disease and treatments:

  • Current treatments for metastatic breast cancer offer modest benefits and a cure remains frustratingly unobtainable.
  • What makes sense, treatment-wise, for any specific woman should be determined by:
    • the characteristics of the disease
    • science-based evidence about a particular treatment
    • the woman's expectations and treatment preferences, as well as her assessment of the treatment's risks and benefits
  • A woman's individual experience with a treatment may be different (and more important to her) than the aggregate results from a clinical trial.
  • Women want and need access to the widest array of beneficial, safe treatment options.
  • Longer progression-free survival is a meaningful benefit for many women.

The U.S. Food and Drug Administration's approval process determines which treatments are available to treat metastatic breast cancer and influences whether insurance companies will cover the treatment.  

As a voice for women diagnosed with metastatic breast cancer, asks you to consider the importance of a woman's access to treatment options. We also ask you to consider the importance of an individual woman's preferences and her perception of treatment benefits.

Thank you.

Marisa Weiss, M.D. on behalf of

President and Founder

Anyone interested in voicing their opinion to the FDA about their decision can write directly to the FDA to have their comments submitted as part of the docket.

In addition, has launched a survey to better understand the breast cancer community's perspective on the FDA's recommendation.  Results will be published on

About is the #1 online resource for medical information and peer support.  A non-profit organization, is dedicated to providing more than 6,000 pages of expert-reviewed information on breast health and breast cancer. receives more than 9 million visits each year.

Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Independent Committee of Caraco Board to Consider Sun Pharma Proposal to Purchase Outstanding Shares
2. Caraco Receives Sun Pharma Proposal to Purchase All Outstanding Shares
3. Cannabis Science Announces a Proposed 10:1 Ratio Structured Dividend Payout for a New Class of Common Shares to Shareholders of Record as of November 30, 2010
4. Pfizer Commences Tender Offer for All Outstanding Shares of King Pharmaceuticals, Inc.
5. Regeneron Pharmaceuticals, Inc. Announces The Sale of 4,500,000 Shares of Common Stock
6. Sanofi-aventis Commences Tender Offer to Acquire All Outstanding Shares of Genzyme for $69 per Share in Cash
7. Endo Pharmaceuticals Successfully Completes Tender Offer for Shares of Penwest Pharmaceuticals
8. Reportlinker Adds Portable and Transport Ventilator Market Shares, Strategies, and Forecasts, Worldwide, 2010 to 2016
9. Essilor Cancels Four Million Shares
10. Watson Completes Acquisition of CRINONE® and PROCHIEVE® Product Line and Shares of Columbia Laboratories
11. Hospira Announces Intention to Complete Tender Offer for Shares of Javelin Pharmaceuticals
Post Your Comments:
(Date:11/26/2015)... Research and Markets ( ) ... Future Horizons and Growth Strategies in the Italian ... Segment Forecasts, Competitive Intelligence, Emerging Opportunities" report ... --> This new 247-page report ... drug monitoring market, including emerging tests, technologies, instrumentation, ...
(Date:11/25/2015)... , Nov. 25, 2015 ... addition of the "Global Brain Monitoring ... offering. --> ) has ... Brain Monitoring Devices Market 2015-2019" report ... and Markets ( ) has announced ...
(Date:11/25/2015)... WASHINGTON , Nov. 25, 2015  The ... Obstetricians and Gynecologists (ACOG), and the March of ... bipartisan Protecting Our Infants Act of 2015 ... the number of newborns born exposed to drugs, ... Since the bill,s introduction, all three organizations have ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... Bayco Products, Inc today announced the introduction of three Nightstick® brand ... choice of three different colors; red ( NSP-1632 ), yellow ( NSP-1634 ) and blue ... hours in constant-on mode, or 27 hours in blinking strobe mode using a fresh set ...
(Date:11/29/2015)... ... November 30, 2015 , ... Gift ideas ... Sublime Beauty NATURALS®. All products are available on Amazon or its webstore. , ... facial serums and USDA Certified Organic Sesame Oil for Oil Pulling," says Kathy ...
(Date:11/29/2015)... Michigan (PRWEB) , ... November 29, 2015 , ... "I ... games. Things that as a Mother and Wife would love to do, I missed. ... that I just happened to call Dr. Zaidan first. They have changed my life ...
(Date:11/29/2015)... (PRWEB) , ... November 29, 2015 , ... NewsWatch featured ... technology products available to consumers. Amanda Forstrom, a technology expert and special reporter for ... be a reality in the future. , It’s the future because flying cars are ...
(Date:11/29/2015)... ... November 29, 2015 , ... While conventional walkers afford considerable help with ... to exercise weights. Fortunately, an inventor from Uniontown, Pa., has found a way to ... the benefits of a standard walker to improve the user’s quality of life. To ...
Breaking Medicine News(10 mins):